drugset

drugset / Trial / NCT06987097

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

NCT06987097 ↗

Not yet recruiting 410 enrolled Nanjing First Hospital, Nanjing Medical University

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.

Timeline

Start: 2025-05-15
Primary completion: 2028-02-28
Completion: 2029-03-01

Publications

Kan JY, Zhang XJ, Yu WD, Yang ZW, Fan FL, Ding GW, Luo J, Li W, Xie DJ, Liu XF, Zhang H, Chen SL. Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial. JACC Asia. 2026 May;6(5):724-732. doi: 10.1016/j.jacasi.2025.12.014. Epub 2026 Feb 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ambrisentan	Small molecule	10 mg	—

Indications